Least square mean calculation for the fully replicate design [General Sta­tis­tics]

posted by PharmCat  – Russia, 2019-11-03 00:46  – Posting: # 20747
Views: 1,815

(edited by mittyri on 2019-11-03 01:44)

Hi Jaimik, Hi all!

» One question for the least square mean calculation for the fully replicate design as per USFDA in SAS.
» ....
» Please share your thoughts … :-)

I think when changes for one value have been done - it was not changes only for formulation, it was changes for sequence and period also. And if you look at model coefficients probably you will find changes in sequence coefficient. estimate is calculated as L*β where L is a vector of known constants. For example if we have 2 sequence, 2 period, 2 formulation, length of β vector is 4 and for one formulation L = [1; 1/2; 1/2; 0] for other L = [1; 1/2; 1/2; 1]. When value changed its lead to changes in sequence part of β, and then to marginal value of each formulation.

I imagine it like this: one part of change is go to current formulation mean value, and some part goes to sequence and period (because it one model), and because sequence is crossed with other formulation it affect on other formulation level.


Edit: Unnecessary quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Mittyri]

Complete thread:

Activity
 Admin contact
20,779 posts in 4,351 threads, 1,444 registered users;
online 21 (0 registered, 21 guests [including 12 identified bots]).
Forum time: 12:09 CEST (Europe/Vienna)

All we know about the world teaches us that the effects of A and B
are always different—in some decimal place—for any A and B.
Thus asking “are the effects different?” is foolish.    John W. Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5